Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Nonclinical evaluation of APL-4098, a novel GCN2 kinase inhibitor, reveals potent anti-leukemic effects through mitochondrial stress induction and synergy with venetoclax, targeting AML blasts and LSCs

View Full Paper
Ask AI
Bookmark
Share

Authors

KBKevin Blighe

Discussion

Loading...

Member takes

Overview

Nonclinical evaluation shows APL-4098 reduces leukemia stem cells and shows synergy with venetoclax in AML.

Key Points

  • The research aims to evaluate the anti-leukemic efficacy of APL-4098 and its mechanism of action in targeting leukemia stem cells.
  • In vitro assays to measure GCN2 activity and cell viability in AML samples.
  • In vivo studies using AML cell line-derived and patient-derived mouse models.
  • RNA sequencing for exploring the mechanism of action and cellular responses to APL-4098.
  • APL-4098 inhibited GCN2 activity with a Ki of 4.4 nM and showed potent anti-leukemic effects.
  • 21 out of 30 primary AML samples exhibited over 50% reduction in cell viability with APL-4098.
  • Combination therapy with venetoclax resulted in significant reduction of LSC counts and enhanced anti-leukemic effects.

Cite This Study

Kevin Blighe (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce2https://doi.org/10.1182/blood-2025-1503
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel potent and selective GCN2 inhibitor, APL-4098, has anti-leukemic activity through dysregulation of mitochondrial function2026 · 2 citations
  2. 2Abstract 618: Preclinical assessment of APL-030, a selective and orally bioavailable inhibitor of the integrated stress response regulator GCN2 with activity against acute myeloid leukemia2024 · 2 citations
  3. 3Efficacy of GCN2 inhibition by a novel small molecule AP030 in acute leukemia.2024
  4. 4Abstract 5718: TGN-1062, a dual CDK7 and FLT3 Inhibitor, shows potent anti-AML activity and synergizes with Venetoclax2024
  5. 5Targeting the Glutamine Transporter SLC1A5 Enhances Sensitivity of Acute Myeloid Leukemia to MLN49242026